


Supplementary Figure S2. OX40L, CD80 and CD86 mRNA-CART treatment induce long lasting protection against re-challenge with the same tumor cell line. mRNA-CART tretaed mice that had completely rejected the tumorwere re-challenged with 10⁷ A20-cells s.c. (orange, n=5) and compared to naïve mice (black., n=5).

Supplementary Figure S3



MFI Serum Cytokines D+22 after Treatement

Supplementary Figure S3. OX40L, CD80 and CD86 mRNA-CART treatment do not result in long term elevated levels of proinflammatory cytokines in serum of treated mice. Mice treated with mRNA-CARTs were assayed for lserum levels of pro-inflammatory cytokines 22 days after last treatent. Aged matched un-treated mice were included as controls. MFI = Mean fluorescent intesity.